Sliwinski, Svenja
Faqar-Uz-Zaman, Sara Fatima
Heil, Jan
Mohr, Lisa
Detemble, Charlotte
Dreilich, Julia
Zmuc, Dora
Bechstein, Wolf O.
Becker, Sven
Chun, Felix
Derwich, Wojciech
Schreiner, Waldemar
Solbach, Christine
Fleckenstein, Johannes
Filmann, Natalie
Schnitzbauer, Andreas A.
Funding for this research was provided by:
Johann Wolfgang Goethe-Universität, Frankfurt am Main
Article History
Received: 22 January 2024
Accepted: 28 March 2024
First Online: 12 April 2024
Declarations
:
: was granted by the Institutional Review Board (IRB) of the Frankfurt University Hospital and by the Federal Institute for Pharmaceuticals and Medical Products (BfArM) on February 7, 2022, as outlined in patients and methods. The study followed the DIN ISO 14155, the MDR, and the MPDG.
: AAS, DZ, and CD are founders of the Capreolos GmbH (limited), a spin-off of Goethe University to set up the regulatory framework for developing a medical device for prehabilitation. JF joined the Capreolos GmbH as shareholder after the Protego Maxima trial was finished. All other authors do not have any direct or indirect conflict of interest.